Artificial Disc Replacement denied as experimental or investigational by Humana?

Humana's specific coverage criteria for artificial disc replacement are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Artificial Disc Replacement as Experimental

Humana's experimental or investigational denial for artificial disc replacement (ADR) means their medical policy concluded that the evidence for ADR does not meet their internal threshold for coverage as an established procedure in your specific clinical context. This denial requires careful analysis: ADR devices have received FDA premarket approval (PMA) for defined indications at specific spinal levels. Whether the experimental designation is legally defensible depends entirely on whether your case falls within those FDA-approved indications or represents an off-label use.

If your surgeon's recommendation falls within the FDA-approved indications for the device — confirmed cervical or lumbar disc disease at an indicated level, appropriate patient selection, absence of exclusion criteria per the device label — then the experimental denial is in direct tension with FDA regulatory status and is a strong candidate for reversal. If the use is off-label (multi-level, or at a level not approved), the appeal is harder but not impossible, and must rely on guideline support and clinical literature rather than FDA approval alone.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, you are entitled to full-and-fair internal review. Request that the reviewing clinician be an orthopedic or neurosurgical specialist. File within the deadline on your denial letter.
• External review: After an adverse internal outcome, independent external review is available. Federal law provides approximately four months from the original denial; your plan documents specify the exact window. IRO reviewers apply a "generally accepted medical practice" standard, not Humana's internal policy threshold.
• Expedited review: When medically urgent — for example, if ongoing neurologic compromise makes delay harmful — request expedited review; typically resolved within 72 hours.

## What to Gather

1. FDA PMA approval documentation: The FDA premarket approval for the specific ADR device your surgeon intends to use, along with its approved indications. This is publicly available on the FDA's 510(k)/PMA database and is the primary rebuttal to an experimental denial. 2. Confirmation that your case is within label: A written statement from your spine surgeon confirming that your diagnosis, spinal level, and clinical presentation fall within the device's FDA-approved indications. 3. Humana's experimental/investigational policy: Obtain the exact version applied. Review its definition of "experimental" — if it requires absence of FDA approval, and FDA approval exists, that is a direct rebuttal. 4. Applicable spine-society guidelines: A reference to relevant NASS, AAOS, or comparable organizational guidance recognizing ADR as an appropriate treatment for appropriate candidates. Your surgeon's letter should cite the relevant organization generically. 5. Clinical documentation of candidacy: Imaging, chart notes, failed conservative-care records confirming your surgical candidacy per the device label's indicated population. 6. Prescriber/surgeon letter: A detailed letter from your spine surgeon rebutting the experimental designation with reference to FDA approval and guideline recognition, and confirming that your case meets labeled indications.

## Criteria-Mapping Structure

Build a rebuttal exhibit: left column lists each element of Humana's experimental/investigational definition; right column documents how ADR fails to meet that definition for your case (FDA PMA approval date, labeled indication, applicable guideline recognition). Attach the FDA PMA summary as Exhibit A and the device's approved labeling as Exhibit B. An external reviewer applying the "generally accepted medical practice" standard will weigh this evidence independently of Humana's internal policy.